LABU241220P103000
- 2.39
- -2.01-45.68%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
PepGen Stock Craters 35% on FDA Clinical Hold
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target
Vertex Pharmaceuticals Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Natera Analyst Ratings
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Annual review | The top ten explosive stocks in the US stock market for 2024 have been released! Applovin emerges as the dark horse of the year in AI, MSTR astonishes the market with a fivefold increase for the year, and Tesla makes a comeback in the last
As of the market close on December 11, the S&P 500 Index has risen by 27% year-to-date, surpassing 6,000 points; the Nasdaq Composite Index has accumulated a rise of over 33%, reaching a milestone of 0.02 million points, exceeding market expectations.
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target